http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Local thin jacketing for the retrofitting of reinforced concrete columns
Yuce, Serkan Z.,Yuksel, Ercan,Bingol, Yilmaz,Taskin, Kivanc,Karadogan, H. Faruk Techno-Press 2007 Structural Engineering and Mechanics, An Int'l Jou Vol.27 No.5
Two series of tests were conducted to investigate the behavior of local thin jacketing for the retrofitting of reinforced concrete (RC) columns. In the first series, four full-scale RC columns with a height of 400 cm and a 30 cm square cross-section were tested under constant axial load and reversed cyclic lateral displacements. The heavily damaged columns were retrofitted with local thin jacketing. Self-compacting concrete (SCC) was used in the production of 7.5 cm thick, four-sided jacketing. The height of the jacketing was 100 cm for one specimen and 200 cm for all others. In the second series, the retrofitted columns were retested with the same axial load and displacement history. The effectiveness of local thin jacketing in the retrofitting of RC columns was examined with respect to lateral strength, stiffness, inelastic load-deformation behavior and energy dissipation.
Real-life ruxolitinib experience in intermediate-risk myelofibrosis
Fatma Arikan,Tayfur Toptas,Isik Kaygusuz Atagunduz,Tarik Ercan,Ozen Oruc,Fergun Yilmaz,Tulin Tuglular 대한혈액학회 2021 Blood Research Vol.56 No.4
Background In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated. Methods The median age of the patients in this cohort was approximately 58 years. Of these, there were 33 patients (57.9%) in INT-1, 23 patients (40.4%) in INT-2, and 1 patient (1.8%) at high risk. Overall, spleen size reduction of at least 35% (spleen response) was achieved in 56.6% and 63.3% of all cohort and INT-1 risk at any time, respectively. Results Symptom response and clinical improvement were observed in 21.7% and 60.7% of patients, respectively. Anemia and thrombocytopenia were prevalent, but manageable. About 73.7% of patients continued treatment during a median follow-up of 22 months. Two-year OS probability was approximately 84.5% (95% CI, 63.1‒94.0%) and 62.3% (95% CI, 37.5‒79.6%) for the intermediate-1 and -2 risk groups, respectively. Conclusion Real-life experience in a community-based hospital confirms the efficacy and safety profile of ruxolitinib in intermediate-risk myelofibrosis. Treatment discontinuation rates were lower than those in clinical trials.